Analgesic Effect of Resistance Training for Breast Cancer Survivors

Summary

Persistent pain after treatment for breast cancer is a major clinical problem, affecting 25-60 % of the patients and is a source of considerable physical disability and psychological distress. Thus, the development of novel interventions to improve pain management for these patients is of clinical importance. Resistance training (RT) is a promising tool to combat a variety of undesirable adverse effects due to breast cancer treatment. Further, research suggests that it may also be able to provide pain-relieving benefits.

Hypothesis: Resistance training will improve pain perception and physical function in the short- and long term compared to a non-training control group.

Conditions

• Breast Cancer
• Surgery
• Chemotherapy Effect
• Radiotherapy Side Effect
• Pain, Chronic

Interventions

OTHER

Training

The experimental group will perform a supervised progressive resistance training program, with five exercises for the upper- and lower body (box squat, bench press, trap bar deadlift, bench pull and lat pulldown), 2x/week for a 12 week period. The program will utilize a flexible progression system through three distinct training phases; 1) 2-4 sets of 10-12 repetitions, 2) 2-4 sets of 6-8 repetitions, 3) 2-4 sets of 2-4 repetitions. Number of sets are adjusted within session according to daily readiness while load is adjusted within and between sessions according to number of reps performed. A 3-5min rest period is provided throughout the program.

OTHER

Control

The control group will be instructed to continue their everyday lifestyle with no specific instruction regarding exercise and/or diet. However, they will be encouraged not to engage in new forms of exercise or physical activity throughout the study period.

Sponsors & Collaborators

• Danish Cancer Society

  collaborator OTHER

• Danish Cancer Survivor and Late Effects Group

  collaborator UNKNOWN

• Universidad de Granada

  collaborator OTHER

• Aalborg University

  lead OTHER

Principal Investigators

• Pascal Madeleine, Dr. Scient · Aalborg University

• Michael Voigt, Ph. D. · Aalborg University

• Mathias Kristiansen, Ph. D. · Aalborg University

• Manuel Arroyo-Morales, Dr. Med · Universidad de Granada

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

80 Years

Sex

FEMALE

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-08-10

Primary Completion

2021-09-23

Completion

2021-09-23

Countries

• Denmark

Study Locations